About Us | DAEWOONG

We are
Innovation Partner

Creating change the world has never seen.

For a better quality of life.

GROUP HISTORY

1977
First in Korea to
automate softgel capsule production
1987
First in Korea to
obtain a patent in genetic engineering
2001
Developed Korea’s first domestically formulated combination digestive medicine
2001
Developed the world’s first EGF-based biopharmaceutical, Korea’s first biotech new drug
2003
First in Korea to develop Coenzyme Q10
2019
First in Asia to receive U.S. FDA approval for a botulinum toxin product
2022
Launched Fexuclue, Korea’s 34th new drug, a P-CAB therapy for gastroesophageal reflux disease
2023
Launched Enblo, Korea’s 36th new drug, an SGLT-2 inhibitor for diabetes

1977
First in Korea to
automate softgel capsule production
1987
First in Korea to
obtain a patent in genetic engineering
2001
Developed Korea’s first domestically formulated combination digestive medicine
2001
Developed the world’s first EGF-based biopharmaceutical, Korea’s first biotech new drug
2003
First in Korea to develop Coenzyme Q10
2019
First in Asia to receive U.S. FDA approval for a botulinum toxin product
2022
Launched Fexuclue, Korea’s 34th new drug, a P-CAB therapy for gastroesophageal reflux disease
2023
Launched Enblo, Korea’s 36th new drug, an SGLT-2 inhibitor for diabetes

DAEWOONG PHILOSOPHY

Company
We achieve sustainable growth built on
technology and trust
Customers
We provide healthcare professionals with
treatment options they can trust
Society
We deliver high-quality medicines
that patients can use with confidence

FROM PHILOSOPHY TO COMPETENCY

R&D
Industry-leading investment in R&D
Open, cross-boundary collaboration
Innovative platform technologies across autoimmune, fibrosis, and oncology
Quality
GMP certification from global regulatory authorities
Industry-leading four-stage smart factory
Optimized production processes and rigorous quality control
Global Network
Global presence across eight overseas subsidiaries and branches
An integrated network spanning R&D, development, manufacturing, and sales
Strengthened local competitiveness through global talent development
Social Contribution
Advancing medical innovation through healthcare professional education
Global scholarship and talent development programs
Supporting the next generation of medical and scientific leaders

WAY OF WORKING

Autonomy
We determine how we work to achieve ambitious goals. We take ownership in choosing the time, space, and methods that enable deep focus.

With autonomy comes responsibility, and through focused execution, we deliver exceptional results.
Growth
We take ownership of our growth and embrace continuous learning to become industry-leading professionals.

Employee growth is Daewoong’s top priority, and we provide diverse opportunities for development and advancement.

ACHIVEMNT HIGHLIGHTS

Sales
1.51.5trillion KRW
2025 Daewoong Pharmaceutical
(Consolidated Basis)
Operating profit
1,9671,967billion KRW
2025 Daewoong Pharmaceutical
(Consolidated Basis)
R&D intensity
15.815.8%
2025 Daewoong Pharmaceutical
(Consolidated Basis)
Global partnerships
100100+
As of December 2025

BUSINESS PORTFOLIO

Pharmaceuticals
Reliable, high-quality therapeutics for real-world care

Leveraging proven technologies and extensive experience, we provide high-quality medicines that are ready for clinical use. In doing so, we enhance treatment confidence and strengthen patient safety.
Biopharmaceuticals
Expanding the frontiers of next-generation medicine

Our portfolio spans from antibody- and protein-based biologics to advanced cell and gene therapies. We go beyond restoring function to unlock new therapeutic possibilities and expand the boundaries of medicine.
Digital Healthcare
Data-driven personalized care and real-time monitoring

We utilize digital technologies such as apps, wearables, and data analytics to support personalized health management and treatment monitoring.
Wellness
Promoting healthier lives through prevention and everyday care

We offer products and services focused on prevention and daily health management. By supporting healthy lifestyles, we help build sustainable habits for long-term well-being.
IT Solutions
Driving digital transformation across the healthcare value chain

We provide IT platforms and solutions for healthcare and pharmaceutical environments. By digitizing the entire process, enable data-driven decision-making and more transparent, efficient operations.